LGX818 for Patients With BRAFV600 Mutated Tumors

Summary

The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Timeline

Start

2014-01-14

Primary completion

2015-09-01

Completion

2015-10-13

Drugs

Indications